BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:COM701 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of COM701\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06888921-10869@assetmemo.bio
DTSTAMP:20261121T004455Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:COM701: Phase 1/2 readout est. (NCT06888921)
DESCRIPTION:COM701\, phase 1/2\, Ovarian Cancer.\nStudy: A Clinical Trial t
 o Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitiv
 e Ovarian Cancer\nEstimated primary completion: March 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/com701#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06888921
URL:https://assetmemo.bio/drug/com701#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
